AU2017293950B2 - Prevention and treatment of atrial fibrillation/flutter with gamma-ketoaldehyde scavengers - Google Patents

Prevention and treatment of atrial fibrillation/flutter with gamma-ketoaldehyde scavengers Download PDF

Info

Publication number
AU2017293950B2
AU2017293950B2 AU2017293950A AU2017293950A AU2017293950B2 AU 2017293950 B2 AU2017293950 B2 AU 2017293950B2 AU 2017293950 A AU2017293950 A AU 2017293950A AU 2017293950 A AU2017293950 A AU 2017293950A AU 2017293950 B2 AU2017293950 B2 AU 2017293950B2
Authority
AU
Australia
Prior art keywords
atrial
alkyl
atrial fibrillation
alkoxy
anp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017293950A
Other languages
English (en)
Other versions
AU2017293950A1 (en
Inventor
Venkataraman Amarnath
Katherine T. MURRAY
L. Jackson ROBERTS II
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vanderbilt University
Original Assignee
Vanderbilt University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vanderbilt University filed Critical Vanderbilt University
Publication of AU2017293950A1 publication Critical patent/AU2017293950A1/en
Application granted granted Critical
Publication of AU2017293950B2 publication Critical patent/AU2017293950B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415—Pyridoxine, i.e. Vitamin B6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
AU2017293950A 2016-07-07 2017-07-07 Prevention and treatment of atrial fibrillation/flutter with gamma-ketoaldehyde scavengers Active AU2017293950B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662359705P 2016-07-07 2016-07-07
US62/359,705 2016-07-07
PCT/US2017/041211 WO2018009875A1 (en) 2016-07-07 2017-07-07 Prevention and treatment of atrial fibrillation/flutter with gamma-ketoaldehyde scavengers

Publications (2)

Publication Number Publication Date
AU2017293950A1 AU2017293950A1 (en) 2019-01-31
AU2017293950B2 true AU2017293950B2 (en) 2023-06-15

Family

ID=60913210

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017293950A Active AU2017293950B2 (en) 2016-07-07 2017-07-07 Prevention and treatment of atrial fibrillation/flutter with gamma-ketoaldehyde scavengers

Country Status (10)

Country Link
US (2) US20190247375A1 (enExample)
EP (1) EP3481505B1 (enExample)
JP (1) JP7179353B2 (enExample)
CN (1) CN110022936A (enExample)
AU (1) AU2017293950B2 (enExample)
BR (1) BR112019000251A2 (enExample)
CA (1) CA3030149A1 (enExample)
ES (1) ES3040735T3 (enExample)
MX (1) MX393913B (enExample)
WO (1) WO2018009875A1 (enExample)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070249562A1 (en) * 2006-04-25 2007-10-25 Friesen Albert D Treatment of atrial fibrillation
WO2011008202A1 (en) * 2009-07-15 2011-01-20 Vanderbilt University Isoketal scavengers and mitigation of disorders involving oxidative injury
US20120157501A1 (en) * 2004-10-20 2012-06-21 Vanderbilt University Isoketal scavengers and mitigation of disorders involving oxidative injury

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6620836B1 (en) * 1997-01-22 2003-09-16 Jay Patrick Antiarrhythmic and tranquilizer composition and treatment
PL2731597T3 (pl) * 2011-07-12 2024-04-29 Vanderbilt University Sposoby leczenia stanu zapalnego i nadciśnienia tętniczego za pomocą wychwytywaczy gamma-ketoaldehydowych

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120157501A1 (en) * 2004-10-20 2012-06-21 Vanderbilt University Isoketal scavengers and mitigation of disorders involving oxidative injury
US20070249562A1 (en) * 2006-04-25 2007-10-25 Friesen Albert D Treatment of atrial fibrillation
WO2011008202A1 (en) * 2009-07-15 2011-01-20 Vanderbilt University Isoketal scavengers and mitigation of disorders involving oxidative injury

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SIDOROVA, T.N. et al., "Reactive [gamma]-ketoaldehydes promote protein misfolding and preamyloid oligomer formation in rapidly-activated atrial cells", JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, (2014), vol. 79, pages 295 - 302. *

Also Published As

Publication number Publication date
CN110022936A (zh) 2019-07-16
AU2017293950A1 (en) 2019-01-31
MX2019000120A (es) 2019-04-01
US20240189291A1 (en) 2024-06-13
EP3481505C0 (en) 2025-09-03
BR112019000251A2 (pt) 2019-04-16
EP3481505B1 (en) 2025-09-03
US20190247375A1 (en) 2019-08-15
EP3481505A1 (en) 2019-05-15
JP2019520389A (ja) 2019-07-18
EP3481505A4 (en) 2020-02-26
MX393913B (es) 2025-03-24
JP7179353B2 (ja) 2022-11-29
CA3030149A1 (en) 2018-01-11
WO2018009875A1 (en) 2018-01-11
ES3040735T3 (en) 2025-11-04

Similar Documents

Publication Publication Date Title
Evans et al. ACE2 activation protects against cognitive decline and reduces amyloid pathology in the Tg2576 mouse model of Alzheimer’s disease
Zeng et al. Neurotrophins enhance CaMKII activity and rescue amyloid-β-induced deficits in hippocampal synaptic plasticity
Trinchese et al. Inhibition of calpains improves memory and synaptic transmission in a mouse model of Alzheimer disease
JP2021066735A (ja) 認知の健康および機能を向上させるための植物抽出物
Sukhorukov et al. Mitochondrial disorders in Alzheimer’s disease
Liu et al. Modulation of synaptic plasticity, motor unit physiology, and TDP-43 pathology by CHCHD10
US20230012209A1 (en) Methods of preventing or treating parkinson's disease by the farnesylation of paris
Zhang et al. Hippocampal iron accumulation impairs synapses and memory via suppressing furin expression and downregulating BDNF maturation
Ranek et al. Muscarinic 2 receptors modulate cardiac proteasome function in a protein kinase G-dependent manner
Varshney et al. Ang (1–7)/Mas receptor-axis activation promotes amyloid beta-induced altered mitochondrial bioenergetics in discrete brain regions of Alzheimer's disease-like rats
Lopez et al. Enhancing endogenous nitric oxide by whole body periodic acceleration elicits neuroprotective effects in dystrophic neurons
WO2016191323A1 (en) Lithium co-crystals for treatment of neuropsychiatric disorders
Palomo et al. The potential role of glycogen synthase kinase 3 inhibitors as amyotrophic lateral sclerosis pharmacological therapy
AU2017293950B2 (en) Prevention and treatment of atrial fibrillation/flutter with gamma-ketoaldehyde scavengers
EP3866779A1 (en) Treatment of neurological diseases
Acun et al. Investigation of Cyclo-Z therapeutic effect on insulin pathway in Alzheimer's rat model: biochemical and electrophysiological parameters
Zhang et al. Protective effect of S14G-humanin against beta-amyloid induced LTP inhibition in mouse hippocampal slices
Sakuma et al. Molecular mechanisms controlling skeletal muscle mass
Sikazwe et al. Alzheimer’s drug discovery maze: a snap view of the past decade’s diverse pharmacological targets for the disorder
Lee et al. Astrocytic MAOB-GABA axis as a molecular brake on repair following spinal cord injury
WO2023133414A2 (en) Selective elimination of senescent cells by ferroptosis induction
Kisvári et al. The effect of acute simvastatin administration on the severity of arrhythmias resulting from ischaemia and reperfusion in the canine: Is there a role for nitric oxide?
US12156879B2 (en) Combining BACE1 inhibitors with mGluR agonists for Alzheimer's disease therapy
Auzmendi et al. Seizures Induce Hypoxia, and Hypoxia Induces Seizures: A Perverse Relationship That Increases the Risk of Sudden Unexpected Death in Epilepsy (SUDEP)
US20220087962A1 (en) Compositions and methods for treating age-related diseases or conditions

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)